Testosterone and luteinizing hormone levels with 100 mg/day oral cyproterone acetate in men.[1] Levels of testosterone decreased by about 80%.[1]
Testosterone levels with 300 mg/week cyproterone acetate or 100 mg/month
estradiol undecylate both by intramuscular injection in men.[2] Solid lines are average and dashed lines highest and lowest levels. Levels of testosterone decreased by 75% with cyproterone acetate and by 91% with estradiol undecylate.[2]
Testosterone levels with 10 mg/day oral cyproterone acetate, different doses of oral
dienogest, or
placebo in healthy young men.[3] Levels of testosterone decreased by 66 ± 4%, from 600 ng/dL to 185 ng/dL.[3]
Testosterone levels with different doses of cyproterone acetate (CPA),
segesterone acetate (SGA),
norethisterone acetate (NETA), and
levonorgestrel (LNG) alone then in combination with transdermal testosterone followed by discontinuation and recovery in healthy young men.[4] Levels decreased by about 65% with cyproterone acetate alone.[4] There were no differences in gonadotropin levels with 10 versus 20 mg/day cyproterone acetate and testosterone levels for the two groups were combined.[4]
Testosterone levels with 5 or 10 mg/day oral cyproterone acetate in men.[5] Levels of testosterone decreased by 52% with 5 mg/day and by 51% with 10 mg/day.[5]
Testosterone levels with 10 mg/day oral cyproterone acetate in men.[6][7][8] Levels of testosterone decreased by about 70%.[6][7][8]
Androgen (mainly testosterone) levels with 10 or 20 mg/day oral cyproterone acetate in men.[9][10] Levels of androgens decreased by about 60% with both 10 mg/day and 20 mg/day.[9][10]
Testosterone levels with 100 to 300 mg/day oral cyproterone acetate and low-dose oral
estrogen in men.[11] The estrogen used was 0.1 mg/day
diethylstilbestrol (DES),[11] which has been described as an "extremely low" dosage.[12] Levels of testosterone were decreased by about 95% with the combination and by about 61% with cyproterone acetate only.[11]
Hormone levels with 1 to 2 mg/day transdermal estradiol gel and 50 mg/day oral cyproterone acetate in transgender women.[13] The mean dosage of estradiol gel increased between 6 and 12 months.[13]
Testosterone levels with estradiol (E2) alone or in combination with an antiandrogen (AA) in the form of
spironolactone (SPL) or cyproterone acetate (CPA) in transfeminine people.[14] Estradiol was used in the form of oral
estradiol valerate (EV) in almost all cases.[14] The dashed horizontal line is the upper limit of the female/castrate range (~50 ng/dL).
Template documentation
Usage
This template can be used to easily insert a number of graphs with detailed captions and pre-provided references into an article.
^
abJacobi GH, Altwein JE, Kurth KH, Basting R, Hohenfellner R (June 1980). "Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial". British Journal of Urology. 52 (3): 208–215.
doi:
10.1111/j.1464-410x.1980.tb02961.x.
PMID7000222.
^
abMeriggiola MC, Bremner WJ, Costantino A, Bertaccini A, Morselli-Labate AM, Huebler D, et al. (May 2002). "Twenty-one day administration of dienogest reversibly suppresses gonadotropins and testosterone in normal men". The Journal of Clinical Endocrinology and Metabolism. 87 (5): 2107–2113.
doi:
10.1210/jcem.87.5.8514.
hdl:
1773/4465.
PMID11994349.
S2CID3251197.
^
abcZitzmann M, Rohayem J, Raidt J, Kliesch S, Kumar N, Sitruk-Ware R, Nieschlag E (May 2017). "Impact of various progestins with or without transdermal testosterone on gonadotropin levels for non-invasive hormonal male contraception: a randomized clinical trial". Andrology. 5 (3): 516–526.
doi:
10.1111/andr.12328.
PMID28189123.
S2CID41502711.
^
abWang C, Yeung KK (March 1980). "Use of low-dosage oral cyproterone acetate as a male contraceptive". Contraception. 21 (3): 245–272.
doi:
10.1016/0010-7824(80)90005-0.
PMID6771091.
^
abMoltz L, Römmler A, Post K, Schwartz U, Hammerstein J (April 1980). "Medium dose cyproterone acetate (CPA): effects on hormone secretion and on spermatogenesis in men". Contraception. 21 (4): 393–413.
doi:
10.1016/s0010-7824(80)80017-5.
PMID6771095.
^
abMoltz L, Römmler A, Schwartz U, Post K, Hammerstein J (1978). "252. Cyproterone acetate (CPA)-a potential male contraceptive: further studies on the interactions with endocrine parameters". Journal of Steroid Biochemistry. 9 (9): 865.
doi:
10.1016/0022-4731(78)90952-4.
ISSN0022-4731.
^
abMoltz L, Römmler A, Schwartz U, Hammerstein J (1978). "Effects of Cyproterone Acetate (CPA) on Pituitary Gonadotrophin Release and on Androgen Secretion Before and After LH-RH Double Stimulation Tests in Men". International Journal of Andrology. 1 (s2b): 713–719.
doi:
10.1111/j.1365-2605.1978.tb00518.x.
ISSN0105-6263.
^
abKoch UJ, Lorenz F, Danehl K, Ericsson R, Hasan SH, Keyserlingk DV, et al. (August 1976). "Continuous oral low-dosage cyproterone acetate for fertility regulation in the male? A trend analysis in 15 volunteers". Contraception. 14 (2): 117–135.
doi:
10.1016/0010-7824(76)90081-0.
PMID949890.
^
abKoch UJ, Lorenz F, Danehl K, Hammerstein J (November 1975). "Über die Verwendbarkeit von Cyproteronacetat zur Fertilitätshemmung beim Mann. Morphologische Veränderungen und Einflüsse auf die Spermienmotilität" [Use of cyproterone acetate for fertility inhibition in the male. Morphologic changes and influences on sperm motility]. Archiv Fur Gynakologie (in German). 219 (1–4): 581–582.
doi:
10.1007/BF00669258.
PMID1243497.
S2CID21841034.
^
abcGoldenberg SL, Bruchovsky N, Rennie PS, Coppin CM (December 1988). "The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma". The Journal of Urology. 140 (6): 1460–1465.
doi:
10.1016/S0022-5347(17)42073-8.
PMID2973529.
^Schröder FH, Radlmaier A (2009). "Steroidal Antiandrogens". In V. Craig Jordan, Barrington J. A. Furr (eds.). Hormone Therapy in Breast and Prostate Cancer. Humana Press. pp. 325–346.
doi:
10.1007/978-1-59259-152-7_15.
ISBN978-1-60761-471-5.
^
abGava G, Cerpolini S, Martelli V, Battista G, Seracchioli R, Meriggiola MC (August 2016). "Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness". Clinical Endocrinology. 85 (2): 239–246.
doi:
10.1111/cen.13050.
PMID26932202.
S2CID30150360.
Testosterone and luteinizing hormone levels with 100 mg/day oral cyproterone acetate in men.[1] Levels of testosterone decreased by about 80%.[1]
Testosterone levels with 300 mg/week cyproterone acetate or 100 mg/month
estradiol undecylate both by intramuscular injection in men.[2] Solid lines are average and dashed lines highest and lowest levels. Levels of testosterone decreased by 75% with cyproterone acetate and by 91% with estradiol undecylate.[2]
Testosterone levels with 10 mg/day oral cyproterone acetate, different doses of oral
dienogest, or
placebo in healthy young men.[3] Levels of testosterone decreased by 66 ± 4%, from 600 ng/dL to 185 ng/dL.[3]
Testosterone levels with different doses of cyproterone acetate (CPA),
segesterone acetate (SGA),
norethisterone acetate (NETA), and
levonorgestrel (LNG) alone then in combination with transdermal testosterone followed by discontinuation and recovery in healthy young men.[4] Levels decreased by about 65% with cyproterone acetate alone.[4] There were no differences in gonadotropin levels with 10 versus 20 mg/day cyproterone acetate and testosterone levels for the two groups were combined.[4]
Testosterone levels with 5 or 10 mg/day oral cyproterone acetate in men.[5] Levels of testosterone decreased by 52% with 5 mg/day and by 51% with 10 mg/day.[5]
Testosterone levels with 10 mg/day oral cyproterone acetate in men.[6][7][8] Levels of testosterone decreased by about 70%.[6][7][8]
Androgen (mainly testosterone) levels with 10 or 20 mg/day oral cyproterone acetate in men.[9][10] Levels of androgens decreased by about 60% with both 10 mg/day and 20 mg/day.[9][10]
Testosterone levels with 100 to 300 mg/day oral cyproterone acetate and low-dose oral
estrogen in men.[11] The estrogen used was 0.1 mg/day
diethylstilbestrol (DES),[11] which has been described as an "extremely low" dosage.[12] Levels of testosterone were decreased by about 95% with the combination and by about 61% with cyproterone acetate only.[11]
Hormone levels with 1 to 2 mg/day transdermal estradiol gel and 50 mg/day oral cyproterone acetate in transgender women.[13] The mean dosage of estradiol gel increased between 6 and 12 months.[13]
Testosterone levels with estradiol (E2) alone or in combination with an antiandrogen (AA) in the form of
spironolactone (SPL) or cyproterone acetate (CPA) in transfeminine people.[14] Estradiol was used in the form of oral
estradiol valerate (EV) in almost all cases.[14] The dashed horizontal line is the upper limit of the female/castrate range (~50 ng/dL).
Template documentation
Usage
This template can be used to easily insert a number of graphs with detailed captions and pre-provided references into an article.
^
abJacobi GH, Altwein JE, Kurth KH, Basting R, Hohenfellner R (June 1980). "Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial". British Journal of Urology. 52 (3): 208–215.
doi:
10.1111/j.1464-410x.1980.tb02961.x.
PMID7000222.
^
abMeriggiola MC, Bremner WJ, Costantino A, Bertaccini A, Morselli-Labate AM, Huebler D, et al. (May 2002). "Twenty-one day administration of dienogest reversibly suppresses gonadotropins and testosterone in normal men". The Journal of Clinical Endocrinology and Metabolism. 87 (5): 2107–2113.
doi:
10.1210/jcem.87.5.8514.
hdl:
1773/4465.
PMID11994349.
S2CID3251197.
^
abcZitzmann M, Rohayem J, Raidt J, Kliesch S, Kumar N, Sitruk-Ware R, Nieschlag E (May 2017). "Impact of various progestins with or without transdermal testosterone on gonadotropin levels for non-invasive hormonal male contraception: a randomized clinical trial". Andrology. 5 (3): 516–526.
doi:
10.1111/andr.12328.
PMID28189123.
S2CID41502711.
^
abWang C, Yeung KK (March 1980). "Use of low-dosage oral cyproterone acetate as a male contraceptive". Contraception. 21 (3): 245–272.
doi:
10.1016/0010-7824(80)90005-0.
PMID6771091.
^
abMoltz L, Römmler A, Post K, Schwartz U, Hammerstein J (April 1980). "Medium dose cyproterone acetate (CPA): effects on hormone secretion and on spermatogenesis in men". Contraception. 21 (4): 393–413.
doi:
10.1016/s0010-7824(80)80017-5.
PMID6771095.
^
abMoltz L, Römmler A, Schwartz U, Post K, Hammerstein J (1978). "252. Cyproterone acetate (CPA)-a potential male contraceptive: further studies on the interactions with endocrine parameters". Journal of Steroid Biochemistry. 9 (9): 865.
doi:
10.1016/0022-4731(78)90952-4.
ISSN0022-4731.
^
abMoltz L, Römmler A, Schwartz U, Hammerstein J (1978). "Effects of Cyproterone Acetate (CPA) on Pituitary Gonadotrophin Release and on Androgen Secretion Before and After LH-RH Double Stimulation Tests in Men". International Journal of Andrology. 1 (s2b): 713–719.
doi:
10.1111/j.1365-2605.1978.tb00518.x.
ISSN0105-6263.
^
abKoch UJ, Lorenz F, Danehl K, Ericsson R, Hasan SH, Keyserlingk DV, et al. (August 1976). "Continuous oral low-dosage cyproterone acetate for fertility regulation in the male? A trend analysis in 15 volunteers". Contraception. 14 (2): 117–135.
doi:
10.1016/0010-7824(76)90081-0.
PMID949890.
^
abKoch UJ, Lorenz F, Danehl K, Hammerstein J (November 1975). "Über die Verwendbarkeit von Cyproteronacetat zur Fertilitätshemmung beim Mann. Morphologische Veränderungen und Einflüsse auf die Spermienmotilität" [Use of cyproterone acetate for fertility inhibition in the male. Morphologic changes and influences on sperm motility]. Archiv Fur Gynakologie (in German). 219 (1–4): 581–582.
doi:
10.1007/BF00669258.
PMID1243497.
S2CID21841034.
^
abcGoldenberg SL, Bruchovsky N, Rennie PS, Coppin CM (December 1988). "The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma". The Journal of Urology. 140 (6): 1460–1465.
doi:
10.1016/S0022-5347(17)42073-8.
PMID2973529.
^Schröder FH, Radlmaier A (2009). "Steroidal Antiandrogens". In V. Craig Jordan, Barrington J. A. Furr (eds.). Hormone Therapy in Breast and Prostate Cancer. Humana Press. pp. 325–346.
doi:
10.1007/978-1-59259-152-7_15.
ISBN978-1-60761-471-5.
^
abGava G, Cerpolini S, Martelli V, Battista G, Seracchioli R, Meriggiola MC (August 2016). "Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness". Clinical Endocrinology. 85 (2): 239–246.
doi:
10.1111/cen.13050.
PMID26932202.
S2CID30150360.